MUNIC: FULL-YEAR 2021 FINANCIAL RESULTS
156% surge in revenue reflecting a post-pandemic rebound in business Huge improvement in adjusted EBITDA1, up €3.3m €5.4m improvement in net result, almost at break-even Free cash flow of €3.2m
Stay updated with breaking news from Immunic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
156% surge in revenue reflecting a post-pandemic rebound in business Huge improvement in adjusted EBITDA1, up €3.3m €5.4m improvement in net result, almost at break-even Free cash flow of €3.2m
Shares of Immunic, Inc. (NASDAQ:IMUX – Get Rating) have been assigned an average rating of “Buy” from the six analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The […]
StockNews.com initiated coverage on shares of Immunic (NASDAQ:IMUX – Get Rating) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the stock. Other analysts have also recently issued research reports about the stock. Wedbush reiterated a “buy” rating and issued a $61.00 price objective on shares of Immunic […]
DGAP-News: Immunic, Inc. / Key word(s): Personnel Immunic, Inc. Announces Promotion of Glenn Whaley, CPA to Chief Financial Officer 16.03.2022 / 11:30 The issuer is solely responsible
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...